Eye treatment – Antares Optical http://www.antaresoptical.com/ Thu, 23 Jun 2022 10:55:08 +0000 en-US hourly 1 https://wordpress.org/?v=5.9 https://www.antaresoptical.com/wp-content/uploads/2022/04/icon-150x105.png Eye treatment – Antares Optical http://www.antaresoptical.com/ 32 32 Protruding Eye Treatment Market Size 2022 – Segmentation and Analysis by Latest Trends, Share, Development and Growth by Regions to 2029 https://www.antaresoptical.com/protruding-eye-treatment-market-size-2022-segmentation-and-analysis-by-latest-trends-share-development-and-growth-by-regions-to-2029/ Thu, 23 Jun 2022 10:53:26 +0000 https://www.antaresoptical.com/protruding-eye-treatment-market-size-2022-segmentation-and-analysis-by-latest-trends-share-development-and-growth-by-regions-to-2029/ The latest released bulging eye treatment market research has assessed the future growth potential of the Eye Care Treatment market and provides useful information and statistics on market structure and size. The report aims to provide market insights and strategic insights to help decision makers make sound investment decisions and identify potential gaps and growth […]]]>

The latest released bulging eye treatment market research has assessed the future growth potential of the Eye Care Treatment market and provides useful information and statistics on market structure and size. The report aims to provide market insights and strategic insights to help decision makers make sound investment decisions and identify potential gaps and growth opportunities. The Prominent Eye Treatment market report will help users to better understand the market, size, share, demand, revenue, future trends and growth prospects for forecast to 2029. In addition, the report also identifies and analyzes changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in the Eye Care market.

Get an Exclusive Sample of this Report to Understand the Full Report Structure (Including Full TOC, Table and Figures)@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bulging-eye-treatment-market

The bulging eye treatment market is expected to witness market growth at a rate of 5.30% during the forecast period from 2021 to 2028. bulging eyes provides analysis and insights into the various factors that are expected to prevail throughout the forecast period while providing their impacts on market growth. The rise of new routes of administration is accelerating the growth of the booming eye treatment market.

Bulging eye is also called proptosis, which is a serious eye condition described by swelling of one or both eye sockets due to inflammation of the tissues behind and around the eye. This trigger pushes the cornea forward and makes it harder for the eyes to lubricate and moisten.

Outraged, Protruding Eye Treatment Market Research Report educates clients on the different strategies used by the major players in the market. These strategies mainly include new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others that strengthen their footprint in this market. Market data analysis and forecasting using the best and consistent statistical models, market share analysis and key trend analysis are the key factors in achieving the unwavering Cancer Treatment market report bulging eyes. Moreover, complex market information is transformed into a simpler version using proven tools and techniques and then provided to users.

The key driving players operating in the market covered in this report:

Horizon Therapeutics plc Santen Pharmaceutical Co., Ltd, Bausch Health, Kala Pharmaceuticals, Pharmos Corp, Akorn, Incorporated, Novartis AG, ALLERGAN, Eyevance Pharmaceuticals LLC, Noveome Biotherapeutics, Inc, OCUNEXUS THERAPEUTICS, INC, Alcon, Merck & Co., Inc , Pfizer Inc, Bristol-Myers Squibb Company, Sanofi, Sun Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Lupine Pharmaceuticals Inc., Bayer AG, among other domestic and global players. Bulging Eyes Treatment market share data is available for Global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East & Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The full report is available (including full table of contents, list of tables and figures, charts and graph) @ https://www.databridgemarketresearch.com/toc/?dbmr=global-bulging-eye-treatment-market

The overall market size has been derived using primary and secondary sources. The research process begins with comprehensive secondary research using internal and external sources to obtain qualitative and quantitative information related to the market. It also provides an overview and forecast for the Global Eyebrightness Treatment Market based on all segmentation provided with respect to five major reasons such as North America, Europe, Asia-Pacific, the Middle East and Africa and South America. Additionally, primary interviews were conducted with industry participants and commentators to validate the data and analysis. Participants who typically take part in such a process include industry experts such as vice presidents, business development managers, market intelligence managers, and national sales managers, as well as outside consultants such as as valuation experts, research analysts, and key opinion leaders specializing in the bulging eye treatment industry. .

Global hemostasis diagnostics market scope and market size

On the basis of treatment, the booming eye treatment market is segmented into drugs and surgeries.

On the basis of drugs, the inflated eye treatment market is segmented into corticosteroids, antibiotics and others.

On the basis of drug type, the booming eye treatment market is segmented into prescription-only and over-the-counter drugs.

Based on route of administration, the booming eye treatment market is segmented into oral, topical and others.

On the basis of end users, the booming eye treatment market is segmented into hospitals, home care, specialty clinics, and others.

Reason to buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Eye Care Market.
  • Highlights key business priorities to guide companies to reform their business strategies and establish themselves in the vast geography.
  • The key findings and recommendations highlight crucial progressive industry trends in the Eye Treatment Market, thereby allowing players to develop effective long term strategies in order to garner their market revenue.
  • Develop/modify business expansion plans using substantial growth offering in both developed and emerging markets.
  • Discuss in depth the global market trends and outlook associated with the factors driving the market, as well as those restraining the growth to some extent.
  • Improve the decision-making process by understanding the strategies that drive business interest with respect to products, segmentation, and industry verticals.

Access the full report@ https://www.databridgemarketresearch.com/reports/global-bulging-eye-treatment-market

Why us?

We encourage you with an urgent detailed knowledge report on the Prominent Eye Treatment Market.

We structure reports to enhance the efficiency of your work process.

Descriptive graphics, logic diagrams and more scientific instruments to give customers more authentic information in successful yet easy-to-grasp illustrations.

We give you a report that educates you about the difficulties and problems in the bulging eye treatment industry and gives you information that is supposed to solve these problems and expand your development potential.

Thank you for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.


Source link

]]>
Tyrvaya nasal spray shows its effectiveness in the treatment of dry eye https://www.antaresoptical.com/tyrvaya-nasal-spray-shows-its-effectiveness-in-the-treatment-of-dry-eye/ Thu, 16 Jun 2022 16:31:36 +0000 https://www.antaresoptical.com/tyrvaya-nasal-spray-shows-its-effectiveness-in-the-treatment-of-dry-eye/ June 16, 2022 1 minute watch Source/Disclosures Published by: Source: Healio Interviews Disclosures: Katz does not report any relevant financial information. ADD A SUBJECT TO EMAIL ALERTS Receive an email when new articles are published on Please provide your email address to receive an email when new articles are […]]]>

June 16, 2022

1 minute watch


Source/Disclosures

Source:

Healio Interviews


Disclosures: Katz does not report any relevant financial information.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

WASHINGTON – In this Healio video perspective from the American Society of Cataract and Refractive Surgery meeting, JI am Katz, MD, discusses a trial evaluating Tyrvaya nasal spray as a treatment for dry eye.


Source link

]]>
Innovative EverTears® Dry Eye Treatment Endorsed by Dr. Pam Theriot in Independent Strong https://www.antaresoptical.com/innovative-evertears-dry-eye-treatment-endorsed-by-dr-pam-theriot-in-independent-strong/ Tue, 17 May 2022 14:45:00 +0000 https://www.antaresoptical.com/innovative-evertears-dry-eye-treatment-endorsed-by-dr-pam-theriot-in-independent-strong/ An industry leader in the treatment of Meibomian Gland Dysfunction and Dry Eye Syndrome has received influential endorsement. ATLANTA, GEORGIA, USA, May 17, 2022 /EINPresswire.com/ — Representatives of ThermaMEDx today announced that its product, EverTears®the world’s first combination of self-heating eye pad and pre-moistened cleansing pad, has received the endorsement of an influential physician. Ben […]]]>

An industry leader in the treatment of Meibomian Gland Dysfunction and Dry Eye Syndrome has received influential endorsement.

ATLANTA, GEORGIA, USA, May 17, 2022 /EINPresswire.com/ — Representatives of ThermaMEDx today announced that its product, EverTears®the world’s first combination of self-heating eye pad and pre-moistened cleansing pad, has received the endorsement of an influential physician.

Ben Nobles, co-founder of ThermaMEDx and former senior executive at optical industry giant Alcon, shared that EverTears® is designed to provide a convenient and affordable OTC dry eye solution that delivers the precise, controlled heat and eyelid cleansing found in many in-office treatments. EverTears® takes advantage of patented technology developed by ThermaMEDx co-founder, Dr. Michel Guillon, to not only relieve dry eye symptoms, but also to help restore the eye’s natural tear film when used as directed. instructions.

Dr. Pam Theriot, in Independent Strong, listed EverTears® as an effective product to offer to patients for home use. She noted that EverTears® is “A sterile eyelid cleansing pad with a thermal component that stays at over 108 degrees for over six minutes. The pads work to unblock eyelid glands, restore oil flow and retain the natural tear layer. Moist heat melts away buildup and opens pores.”

Independent Strong is an online resource providing the information independent eyecare professionals need to thrive now and in the future. Independent Strong provides the step-by-step guidance that new and established private optometrists and opticians need to build and maintain a systematic structure and aims to serve as the foundation of their business for years to come. It also provides updated feature articles with engaging and current best practice advice on a variety of topics categorized in practice management, practice growth strategies, and ophthalmic products.

New business and practice advisory information released regularly by industry experts and partners helps private practitioners make their independent practices as successful and useful as possible.

For more information, please visit thermamedx.com/about-us

About ThermaMEDx

ThermaMEDx was founded to bring Dr. Michel Guillon’s vision of harnessing thermal energy to provide an accessible and effective treatment for dry eyes and meibomian gland dysfunction. ThermaMEDx is a family business led by our Medical Board of renowned physicians whose mission is to improve patient outcomes by striving to provide the best treatment for dry eyes caused by Meibomian Gland Dysfunction (MGD) available. for home use.

Contact details:

3343 Peachtree Road NE
ETS 145-409
Atlanta, Georgia 30326
United States

Carl Sweat
ThermaMEDx, LLC
+1 833-937-9393
write to us here


Source link

]]>
Protruding Eye Treatment Market Size 2022-Industry Opportunities and Challenges, Global and Regional Analysis by Key Industry Players https://www.antaresoptical.com/protruding-eye-treatment-market-size-2022-industry-opportunities-and-challenges-global-and-regional-analysis-by-key-industry-players/ Tue, 10 May 2022 11:36:05 +0000 https://www.antaresoptical.com/protruding-eye-treatment-market-size-2022-industry-opportunities-and-challenges-global-and-regional-analysis-by-key-industry-players/ A new market study on Global bulging eye treatment market 2022 with + data tables, pie chart and graphs is published to provide a comprehensive assessment of the market highlighting evolving trends, current and future scenario analysis and growth factors validated with expert view. The study breaks the market in terms of revenue and volume […]]]>

A new market study on Global bulging eye treatment market 2022 with + data tables, pie chart and graphs is published to provide a comprehensive assessment of the market highlighting evolving trends, current and future scenario analysis and growth factors validated with expert view. The study breaks the market in terms of revenue and volume (if applicable) and historical price estimates for Bulging Eye Treatment. Protruding Eye Treatment Market analysis report helps increase sales through new thinking, new skills, and innovative programs and tools. Through the study of Competitor Analysis, the Eye Cream industry can gain knowledge of the strategies of key players in the market, which include but are not limited to new product launches, expansions , agreements, joint ventures, partnerships and acquisitions.

Connect with market leaders and emerging players inThis market.

To learn more about market size, share, growth, trends and company profile analysis, please download our free sample report @ @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bulging-eye-treatment-market

(Sample of this report is readily available on demand with Impact of COVID-19 on this Industry)

Content of this sample report:
? A brief introduction to this research scope and methodology.
? Revenue analysis of leading and emerging players.
? Key highlights of growth drivers and market trends.
? Key overview of the final study.
? Graphic illustration of regional analysis.

The bulging eye treatment market The report encompasses the general idea of ​​the global Protruding Eye Treatment market including definition, classifications, and applications. Also, it includes comprehensive understanding of several factors such as drivers, restraints, and major micro markets. The report is an extensive source of popular facts and figures for business strategists as it offers historical and futuristic data such as demand & supply data, cost, revenue, profit, value of supply chain, etc. Additionally, it features key market features including production, revenue, price, capacity, gross margin, market share, consumption, gross rate, production rate, demand/ supply, cost, capacity utilization rate, export/import and CAGR (annual compound). Rate of growth). Further, the report encompasses segmentation of the global bulging eye treatment market on the basis of various facets such as product/service type, application, technology, end-users and major geographical regions North America, Europe, Asia-Pacific and Latin America. Apart from this, the researcher market analyst and experts present their outlook or ideas on product sales, market share, and value, and possible opportunities for growth or operation in these regions.

Bulging Eyes Treatment Market Scenario

Bulging eye is also known as exophthalmos, a serious eye condition characterized by the protrusion of one or both eye sockets due to swelling of the tissues behind and around the eye. This causes the cornea to push forward and makes it more difficult for the eyes to get moisture and lubrication. In most cases, bulging eyes can create a large amount of pressure on the optic nerve, potentially leading to vision loss.

Key segmentation:

By treatment (drugs, surgery)

By medication (corticosteroids, antibiotics and others)

By drug type (prescription only, over-the-counter drugs)

By route of administration (oral, topical and others)

By end users (hospitals, home care, specialist clinics, others)

Major players operating in the bulging eye treatment market are:

Horizon Therapeutics plc Santen Pharmaceutical Co., Ltd

Bausch Health

Kala Pharmaceuticals

Pharmos Corp.

Akorn, Incorporated, Novartis SA

ALLERGAN

Eyevance Pharmaceuticals LLC

Noveome Biotherapeutics, Inc.

…..

The full report is available (including full table of contents, list of tables and figures, charts and graph) @https://www.databridgemarketresearch.com/toc/?dbmr=global-bulging-eye-treatment-market

The bulging eye treatment market report also involves a vigorous assessment of the growth plot and all the opportunities and risks related to the global bulging eye treatment market during the forecast period. In addition, the report includes key events and up-to-the-minute industry innovations, as well as forward-looking trends of technological advancement within the Global Eyebrightness Treatment Market that may impact its expansion graph. Containing the essential data on statistics and market dynamics, the report will be a valuable asset in terms of decision-making and guidance for companies and companies already active in the industry or wishing to enter it.

Promising Regions & Countries Mentioned In The Swelling Eyes Treatment Report:

North America ( United States)

Europe (Germany, France, United Kingdom)

Asia Pacific (China, Japan, India)

Latin America (Brazil)

The Middle East and Africa

For more information or query or customization before buying, visit @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bulging-eye-treatment-market

Market factors

The increasing prevalence of hyperthyroidism cases and related complications is driving the growth of this market

Introducing new delivery routes that improve drug efficacy can boost the market growth

Advances in nutrition, antibiotics and new treatments are driving the market growth

Huge financial support to researchers for development of new intervention enhances market growth

Market constraints

The anatomical and physiological barrier of the eyes that makes it difficult to obtain therapeutic benefits is restraining the growth of the market

The lesser effectiveness of available treatments hammers the growth of the market

Scientific and technological challenges to develop a new treatment acting as a challenge factor for the growth of this market

Reason to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Eye Care Market.

Highlights key business priorities to help companies realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the Bulging Eye Treatment, thereby allowing players to develop effective long term strategies.

Develop/modify business expansion plans using substantial growth offering in both developed and emerging markets.

Dig deep into the global market trends and outlook associated with the factors driving the market, as well as those hindering it.

Improve the decision-making process by understanding the strategies that drive business interest with respect to products, segmentation, and industry verticals.

Access the full report directly @https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-bulging-eye-treatment-market

In addition, the research report examines:

Competitive companies and manufacturers in the global market

By product type, applications and growth factors

Industry status and outlook for major applications/end-users/usage area

Containment and care products and other dental consumables Table of contents

Report Overview: It includes the objectives and scope of the study and provides highlights of key market segments and players covered. It also includes the years considered for the research study.

Executive Summary: It covers industry trends with a focus on market use cases and key market trends, market size by region and global market size. It also covers market share and growth rate by region.

Key Players: Here, the report focuses on mergers and acquisitions, expansions, analysis of key players, date of establishment of companies and areas served, manufacturing base and revenue of key players.

Breakdown by Product and Application: This section provides market size details by product and application.

Regional Analysis: All of the regions and countries analyzed in the report are studied on the basis of market size by product and application, key players and market forecast.

International Player Profiles: Here, players are rated based on their gross margin, price, sales, revenue, activity, products and other company information .

Market Dynamics: It includes supply chain analysis, regional marketing analysis, challenges, opportunities, and drivers analyzed in the report.

Main results of the research study

Appendix: It includes details of the research approach and methodology, research methodology, data sources, study authors and a disclaimer.

Browse Full Report Details @https://www.databridgemarketresearch.com/reports/global-bulging-eye-treatment-market

Thank you for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Data Bridge Market Research allows you to customize the reports according to your needs. This report can be customized to meet your needs. Contact our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you get a report that suits your needs.


Source link

]]>
Dry eye treatment improves signs and symptoms at 1 week https://www.antaresoptical.com/dry-eye-treatment-improves-signs-and-symptoms-at-1-week/ Tue, 03 May 2022 20:08:10 +0000 https://www.antaresoptical.com/dry-eye-treatment-improves-signs-and-symptoms-at-1-week/ Source/Disclosures Published by: Source: Wirta D, et al. Dry eye signs, symptoms and quality of life improvements associated with AR-15512 administration. Presented at the Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver. Disclosures: Wirta reports receiving a grant from Aerie Pharmaceuticals as the principal investigator for this study. […]]]>


Source/Disclosures

Source:

Wirta D, et al. Dry eye signs, symptoms and quality of life improvements associated with AR-15512 administration. Presented at the Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.


Disclosures: Wirta reports receiving a grant from Aerie Pharmaceuticals as the principal investigator for this study.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

DENVER – A large Phase 2b study has shown that using Aerie Pharmaceuticals’ compound AR-15512 resulted in improved tear production and dry eye symptoms at 7 days and 14 days, according to David Wirtone, MD, from the Eye Research Foundation.

The cold thermoreceptor agonist TRPM8 affects receptors in the conjunctiva, cornea and eyelid to stimulate a feeling of coldness in the eye, resulting in reflex tearing, Wirta said.


Source link

]]>
Bloated eye treatment market to grow at a torrid pace, key players -Bausch Health. – ManufactureLink https://www.antaresoptical.com/bloated-eye-treatment-market-to-grow-at-a-torrid-pace-key-players-bausch-health-manufacturelink/ Mon, 02 May 2022 10:22:03 +0000 https://www.antaresoptical.com/bloated-eye-treatment-market-to-grow-at-a-torrid-pace-key-players-bausch-health-manufacturelink/ New York, United States: A new report from Critical market insights examine the Booming eye treatment market from a global perspective and analyzes industry trends and prospects. Primary and secondary research analysis could be included in this report, which will provide market size, dynamics and forecast for different segments and sub-segments considering both macro and […]]]>

New York, United States: A new report from Critical market insights examine the Booming eye treatment market from a global perspective and analyzes industry trends and prospects. Primary and secondary research analysis could be included in this report, which will provide market size, dynamics and forecast for different segments and sub-segments considering both macro and micro factors. Extensive research on historical trends, projected trends, demographics, technological developments, and regulatory requirements have all been reviewed to determine market expansion rates for each segment and sub-segment.

Quickly take advantage of limited sample copies of the Booming eye treatment market report: visit @ https://www.decisivemarketsinsights.com/bulging-eye-treatment-market/36872504/request-sample

Protruding Eye Treatment Market Segmentation-
By type:
Medicine, Surgery
Per application:
Oral, topical and others
By key players: Bausch Health, Kala Pharmaceuticals, Pharmos Corp, Akorn, Incorporated, Novartis AG, ALLERGAN, Eyevance Pharmaceuticals LLC, Noveome Biotherapeutics, Inc, OCUNEXUS THERAPEUTICS, INC, Alcon, Merck & Co

The report contains substantial details about the functioning of the parent market. The report provides accurate projections of market size and volumes in the present and future. During the forecast period, our analysts provide our clients with comprehensive data to help them create growth plans and policies that enhance growth. The findings of our in-depth study of the world Booming eye treatment market reveal the economic cycle and paradigm shifts related to Covid-19. A number of key findings from the report are offered, shedding light on trends that may have a significant impact on the market growth ahead.

To inquire about the discount, please fill out the form by clicking the link below:- https://www.decisivemarketsinsights.com/bulging-eye-treatment-market/36872504/request-discount

This global Booming eye treatment market How will the report benefit you?
• Statistical data is provided in terms of value (US dollars) and volume (units) up to 2027.
• A detailed analysis of global trends affecting the XX market, although the major threats, opportunities, and disruptive technologies may influence global demand and supply.
• In the report on Booming eye treatment market primary and secondary data sources are combined to analyze the data.
• Using this report, you can determine the true effects of major market forces or trends on Booming eye treatment market .
• We accumulate adequate data by conducting extensive primary research with C-level executives from top companies.
• The report tracks and profiles key market players who will shape and affect the global market in the coming years.

Please click on the link below if you intend to make a direct purchase @:-https://www.decisivemarketsinsights.com/bulging-eye-treatment-market/36872504/buy-now

The report also contains several other key points, including:
• An analysis of the competitive landscape is also included in the report.
• A detailed analysis of key players’ product offerings and strategies is provided in this report.
• The report presents historical, current and projected market sizes in terms of volume and value.
• The report includes a detailed explanation of recent industry developments and trends.
• By studying the strategies used by market players to maintain and strengthen their footprint, readers gain a comprehensive understanding of their actions.
• A segment with high growth potential, as well as a region, will be analyzed.
• This report also analyzes market dynamics and details with detailed information.

In order to make a pre-order request, please click on the link below:-https://www.decisivemarketsinsights.com/bulging-eye-treatment-market/36872504/pre-order-enquiry

Please contact us and our expert will get back to you within 30 minutes:

Critical market insights
Sunil Kumar
Head of sales
E-mail -[email protected]
Website-https://www.decisivemarketsinsights.com/
United States +18317045538
UK +441256636046
Address:- 26 Broadway, Suite 934, New York, 10004

Social connections:
Twitter-https://twitter.com/decisivemarket

Linkedin-https://www.linkedin.com/company/decisive-markets-insights



Source link

]]>
Emirates News Agency – 33 million beneficiaries thanks to Noor Dubai eye treatment and prevention programs worldwide https://www.antaresoptical.com/emirates-news-agency-33-million-beneficiaries-thanks-to-noor-dubai-eye-treatment-and-prevention-programs-worldwide/ Fri, 29 Apr 2022 11:40:22 +0000 https://www.antaresoptical.com/emirates-news-agency-33-million-beneficiaries-thanks-to-noor-dubai-eye-treatment-and-prevention-programs-worldwide/ DUBAI, 29th April, 2022 (WAM) — The Noor Dubai Foundation, one of the Mohammed bin Rashid Al Maktoum Global Initiatives, has managed to benefit 33 million people worldwide, through its treatment, prevention and awareness specializing in the prevention of blindness. This was reported at the annual meeting of the Mohammed bin Rashid Al Maktoum Global […]]]>

DUBAI, 29th April, 2022 (WAM) — The Noor Dubai Foundation, one of the Mohammed bin Rashid Al Maktoum Global Initiatives, has managed to benefit 33 million people worldwide, through its treatment, prevention and awareness specializing in the prevention of blindness.

This was reported at the annual meeting of the Mohammed bin Rashid Al Maktoum Global Initiatives Foundation, where an inspiring patient story was shared, also documenting Noor Dubai’s journey since its launch in 2008.

His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President, Prime Minister and Ruler of Dubai, tweeted on his personal account yesterday expressing his pride that 145,000 volunteers have joined the initiatives in 2021, while His Highness also tweeted, ” proud of Noor Dubai which has reached 33 million beneficiaries.”

Since its launch as an initiative by His Highness Sheikh Mohammed bin Rashid Al Maktoum in 2008, Noor Dubai has helped care for those in need in 22 countries around the world, supporting humanitarian efforts and community prosperity. Following the success of the initiative in its first year, HH launched Noor Dubai as a foundation in 2010.

Despite the progress made by Noor Dubai and other institutions in this area, there is still a need to provide eye care services to those in need. According to statistics published by the World Health Organization, 295 million people worldwide suffer from visual impairment, 80% of them can be treated or prevented from developing visual impairment and 90% of people with visual impairment reside in developing countries.

Despite the challenges facing the world, especially the humanitarian sector, due to the spread of the Covid-19 pandemic globally, Noor Dubai was able to overcome all the challenges in one year and exceed its targeted beneficiaries to reach 33 million beneficiaries in a short time. of time.

The Noor Dubai Foundation programs focus on supporting the acceleration of United Nations Sustainable Development Goals 1, 3, 4, 5, 17 by developing programs and strategies for eye health in Africa and around the world. Asia that aim to empower the local community to control the disease, which will have a positive impact on the economic development of the countries where the treatment took place.

Nationally, the Foundation provides free eye screenings and consultations to the UAE community through the Mobile Eye Clinic program, which has benefited 30,050 patients since the program launched in 2014.

The clinic aims to offer eye exams to patients in their place in various parts of the country through the implementation of prevention campaigns.

The campaigns mainly focus on public transport drivers, community schools and work accommodation to ensure that eye exam services are accessible to all members of the community.

The Foundation also provides treatment to UAE residents who suffer from serious eye diseases through the UAE Treatment Program, which has successfully provided treatment to 245 patients since its launch in 2016.

Globally, the Noor Dubai Foundation runs Mobile Eye Camps in remote areas of Asia and Africa, where the lack of healthcare infrastructure and sanitation resources in these remote areas, in addition to extreme poverty, makes it difficult for patients to access the services they need. 319,280 patients benefited from the program through diagnostic and treatment services.

The Noor Dubai Foundation is also continuing its journey in the fight against neglected tropical diseases through the trachoma eradication program in northern Ethiopia. The Foundation succeeded in eliminating trachoma as a public health problem in 29% of the Amhara region and treated 18 million people.

Trachoma is one of the leading causes of blindness worldwide, with more than 1.9 million people suffering visual impairment as a result of complications from trachoma. As a member of the Neglected Tropical Disease NGO Network (NNN) and the International Coalition for Trachoma Control (ICTC), the Noor Dubai Foundation is involved in shaping policy for the control of neglected tropical diseases that affect one billion of people in the world.

In line with its strategic direction for comprehensive and long-term programs, in 2019 Noor Dubai launched an eye care program in Katsina State, Nigeria, where all program activities were integrated into the public health system, including the development of local care, human, material and infrastructure capacities and resources.

The program aims to improve the quality of life and socio-economic status of residents of Katsina State and will help reduce blindness and visual impairment in the state by at least 30-40%. To date, more than 24,000 patients have received medical and diagnostic services and 7.5 million people have benefited from public health programs aimed at educating about diseases causing visual impairment.

In 2021, Noor Dubai launched a 5-year program in partnership with the Fred Hollows Foundation, to reduce avoidable blindness by strengthening the eye health system to provide a more comprehensive and sustainable approach in addition to providing eye care services gender-equitable and disability-inclusive in the Barishal Division of Bangladesh.

The program aims to provide effective and affordable prevention, treatment and management of refractive error and diabetic retinopathy, the leading causes of blindness in Barishal.

This program should benefit 25,000 children, 50,000 adults and sensitize and educate nearly 4 million people in Barisal.


Source link

]]>
Cationorm – a preservative-free dry eye treatment https://www.antaresoptical.com/cationorm-a-preservative-free-dry-eye-treatment/ Thu, 21 Apr 2022 04:53:00 +0000 https://www.antaresoptical.com/cationorm-a-preservative-free-dry-eye-treatment/ Cationorm (cationic nanoemulsion) is a preservative-free moisturizing and lubricating emulsion that protects the surface of the eye, reducing the discomfort and irritation of persistent dry eyes caused by prolonged contact lens wear or environmental conditions.1 The therapy’s triple action repairs the lipid layer to reduce evaporation, lubricates and stabilizes the tear film; restores the moisture […]]]>

Cationorm (cationic nanoemulsion) is a preservative-free moisturizing and lubricating emulsion that protects the surface of the eye, reducing the discomfort and irritation of persistent dry eyes caused by prolonged contact lens wear or environmental conditions.1

The therapy’s triple action repairs the lipid layer to reduce evaporation, lubricates and stabilizes the tear film; restores the moisture balance in the muco-aqueous layer of the tear film; and is positively attracted to the ocular surface, to provide long-lasting protection.2-5

Cationorm is suitable for use with contact lenses and is easily administered via a preservative-free multi-dose vial or single-dose ampoules.6

It can be given as one drop, up to four times a day in the affected eye or eyes.6

ALWAYS FOLLOW THE INSTRUCTIONS. IF SYMPTOMS PERSIST, TALK TO YOUR HEALTHCARE PROFESSIONAL.

To order Cationorm, contact Good Optical Services: 1800 814 963 or orders@goodopticalservices.com.au

For more information contact Seqirus Medical Information: 1800 642 865 or aunz.medicalinformation@seqirus.com.

References

  1. Administration of Therapeutic Goods. Australian Therapeutic Goods Register – Public Summary Seqirus PTY LTD – Lubricant, Eye.[cited2021;Availableat:https://wwwebstgagovau/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStorensf&docid=406945E40B6D2CA4CA25843C0042145B&agid=(PrintDetailsPublic)&actionid=1[cited2021;Availablefrom:https://wwwebstgagovau/servlet/dbid=ebs6?PublicHTML/pdfStorensf&docid=406945E40B6D2CA4CA25843C0042145B&agid=(PrintDetailsPublic)&actionid=1[citéen2021 ;Disponiblesur:https://wwwebstgagovau/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStorensf&docid=406945E40B6D2CA4CA25843C0042145B&agid=(PrintDetailsPublic)&actionid=1[cited2021;Availablefrom:https://wwwebstgagovau/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStorensf&docid=406945E40B6D2CA4CA25843C0042145B&agid=(PrintDetailsPublic)&actionid=1
  2. Lallemand, F., et al., Successful improvement of ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv, 2012. 2012: p. 604204.
  3. Daull, P., F. Lallemand, and JS Garrigue, Advantages of cationic oil-in-water nanoemulsions of cetalkonium chloride for topical delivery of ophthalmic drugs. J Pharm Pharmacol, 2014. 66(4): p. 531-41.
  4. Amrane, M., et al., Ocular tolerance and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease–a randomized comparative study. J Fr Ophthalmol, 2014. 37(8): p. 589-98.
  5. Robert, PY, et al., Efficacy and safety of a cationic emulsion in the treatment of moderate to severe dry eye disease: a randomized controlled study. Eur J Ophthalmol, 2016. 26(6): p. 546-555.
  6. Cationorm product packaging.


Source link

]]>
Mann Eye Institute Expands Innovative EverTears Dry Eye Treatment After Extensive Evaluation https://www.antaresoptical.com/mann-eye-institute-expands-innovative-evertears-dry-eye-treatment-after-extensive-evaluation/ Tue, 19 Apr 2022 14:45:00 +0000 https://www.antaresoptical.com/mann-eye-institute-expands-innovative-evertears-dry-eye-treatment-after-extensive-evaluation/ An industry leader in dry eye treatment has partnered with an innovative medical device start-up to deliver an effective dry eye treatment. ATLANTA, GEORGIA, USA, April 19, 2022 /EINPresswire.com/ — Representatives of ThermaMEDx today announced that the Mann Eye Institute has partnered with the company to evaluate EverTears, the world’s first combination compress self-heating eyepiece […]]]>

An industry leader in dry eye treatment has partnered with an innovative medical device start-up to deliver an effective dry eye treatment.

ATLANTA, GEORGIA, USA, April 19, 2022 /EINPresswire.com/ — Representatives of ThermaMEDx today announced that the Mann Eye Institute has partnered with the company to evaluate EverTears, the world’s first combination compress self-heating eyepiece and pre-moistened cleaning pad.

Carl Sweat, co-founder of ThermaMEDx, said EverTears is designed to provide a convenient and affordable over-the-counter dry eye solution that delivers the precise, controlled heat and eyelid cleansing found in many in-office treatments. EverTears is based on patented technology developed by ThermaMEDx co-founder, Dr. Michel Guillon, to not only relieve dry eye symptoms, but also help restore the eye’s natural tear film when used. in accordance with the instructions.

Mann Eye Institute is the premier provider of LASIK eye surgery, dry eye treatment, and general eye care in the greater Houston area and one of the largest private eye care practices in Texas.

Mann Eye Institute CEO and Executive Director, Dr. Dana Ondrias, explained that providing innovative eye care has long been a key part of the organization’s mission: “Just like our founder, Dr. Mike Mann, Being one of the first physicians in America to perform refractive surgery in 1981, our dedicated staff embraces innovative solutions that advance patient care. She added: “Our doctors and staff started giving the EverTears treatment to dry eye patients late last year and we were pleased with both the patient feedback and the improvement in their condition. underlying MGD.” Based on the test results, the Mann Eye Institute is expanding EverTears to additional Texas sites as the standard of care for dry eye treatment.

ThermaMEDx co-founder Ben Nobles was particularly excited about the expansion plans, saying “Texas is the epicenter of dry eye disease in America and innovative organizations like the Mann Eye Institute are at the forefront. -care to bring the latest technology to their patients.We are committed to supporting the implementation of EverTears as the best treatment for dry eye disease related to Meibomian Gland Dysfunction (MGD).

For more information, please visit thermamedx.com/about-us and https://thermamedx.com/insights-news/

About ThermaMEDx

ThermaMEDx was founded to bring Dr. Michel Guillon’s vision of harnessing thermal energy to provide an accessible and effective treatment for dry eyes and meibomian gland dysfunction. ThermaMEDx is a family business led by our Medical Board of renowned physicians whose mission is to improve patient outcomes by striving to provide the best treatment for dry eyes caused by Meibomian Gland Dysfunction (MGD) available. for home use.

Contact details:

3343 Peachtree Road NE
ETS 145-409
Atlanta, Georgia 30326
United States

Carl Sweat
ThermaMEDx, LLC
+1 833-937-9393
write to us here


Source link

]]>
Longer-acting eye treatment could reduce vision loss for Indigenous Australians https://www.antaresoptical.com/longer-acting-eye-treatment-could-reduce-vision-loss-for-indigenous-australians/ Tue, 19 Apr 2022 01:24:00 +0000 https://www.antaresoptical.com/longer-acting-eye-treatment-could-reduce-vision-loss-for-indigenous-australians/ Indigenous people in Australia experience three times more vision loss than non-indigenous people, creating a worrying gap in vision. This is largely due to diabetic macular edema (DME). Here, the blood vessels at the back of the eye (the retina) are damaged by high blood sugar. Over time, this causes swelling (oedema) of the central […]]]>

Indigenous people in Australia experience three times more vision loss than non-indigenous people, creating a worrying gap in vision.

This is largely due to diabetic macular edema (DME). Here, the blood vessels at the back of the eye (the retina) are damaged by high blood sugar. Over time, this causes swelling (oedema) of the central part of the retina (the macula).

Macular edema blurs central vision, impairing the ability to recognize people’s faces, drive and work, and perform other essential tasks. DMO affects around 23,000 Indigenous people in Australia, most of whom are of working age. Similar trends are reported in other developed states with indigenous populations, including New Zealand, Canada, and the United States.

The good news is that BMD can be treated, with drugs called anti-VEGF agents. We have undertaken a world-first clinical trial to test a longer-acting BMD treatment for Indigenous Australians. In doing so, we have also learned to undertake culturally sensitive research about the country.



Learn more: How can the new Closing the Gap dashboard highlight metrics and targets that are on track?


A longer lasting treatment

When injected into the eye by an ophthalmologist (eye surgeon), anti-VEGF drugs are safe and effective for treating DME. The injections do not hurt, since the eye is anesthetized. The catch is that anti-VEGF agents have a relatively short duration of action, requiring them to be re-administered as often as monthly.

Many Aboriginal patients find it impractical, for a variety of complex reasons, to attend ten to twelve eye appointments per year. So there is a need for an alternative.

Longer acting drugs exist. An example is an implant of dexamethasone (commercially known as Ozurdex(R)), a steroid injected into the eye. The dexamethasone implant only needs to be dosed every three months.

The dexamethasone implant is PBS-approved for BMD in Australia, but has never been evaluated in an aboriginal population. This is important because a possible side effect of steroid medications is increased pressure in the eye. If left untreated, it can lead to a condition called steroid-induced glaucoma.

Glaucoma is thought to occur less frequently in Aboriginal people, suggesting differences in eye pressure physiology between Caucasian and Aboriginal eyes. In addition, the incidence of steroid-induced glaucoma subtype has never been studied in Aboriginal people. This is especially important for people living in remote areas, as glaucoma is a ‘silent disease’, requiring regular check-ups for detection and treatment.

Historical barriers preventing this type of research include cultural and geographic factors, as well as a lack of endorsement from Indigenous health services and “staff champions”.

Kerry Woods, of the Plangermairreenner clan of the Ben Lomond people, is an Indigenous eye health coordinator involved in the study. She said it gave her insight into the treatments available for diabetic eye disease and the monthly injections needed to manage the condition. […] By working closely with patients, I have the opportunity to discuss treatments and find out if they are more satisfied with the new schedule.
Author provided

Not only what to look for, but how

At Lions Eye Institute, we sought to overcome these barriers with the OASIS Study – a world-first clinical trial in ophthalmology to exclusively recruit Indigenous patients.

We framed our study around ten key success factors, including support from all participating Indigenous medical services, free and safe treatment, free transportation, appointment reminders, and cultural safety training for all staff. test staff. Whenever possible, study visits were conducted within the patient’s usual Aboriginal medical service. Study participants could be accompanied by friends, family and staff. This facilitated communication and a sense of security and trust.

Over two years, we recruited 38 aboriginal patients and 52 eyes (some patients had BMD in both eyes). Patients were recruited from both Perth and Western Australia. When they enrolled, they were randomly assigned to receive a dexamethasone implant or an anti-VEGF agent called Avastin. A follow-up was carried out for checks and restatements. After 12 months, we analyzed all our data, in order to compare the safety and effectiveness of the two drugs.

The results showed that patients who received a dexamethasone implant gained an additional four letters on a standard eye chart, which equated to a 6.2% improvement in their vision. Those who received the anti-VEGF agent, meanwhile, lost 5.5 letters on average, a drop of 8.9%.

Taken together, these results represented a visual benefit of 15% (9.5 letters) for patients who received a dexamethasone implant. In concrete terms, this meant that the patients met the visual requirements for a private driving license. Those who received the anti-VEGF agent did not receive it.

This disparity was more pronounced in rural towns, where the dexamethasone implant had a 37% advantage (24 letters) over the anti-VEGF agent.

map of WA with point ids
Trial participants came from across Western Australia.
Author provided

why it works

As we suspected, the reason for the better performance of the dexamethasone implant had to do with its less frequent, and therefore more pragmatic, dosing schedule.

Over 12 months, patients who were to receive four dexamethasone implant injections received an average of 3.3 injections. This means that, on average, they received 82.5% of the scheduled treatments.

Anti-VEGF patients, meanwhile, received 7.2 of their 12 scheduled injections. This equates to only 60% of their scheduled treatments and reflects the difficulty of attending monthly appointments in the real world. Anti-VEGF patients received more than twice as many injections as patients with dexamethasone implants, but ended up with poorer vision.

Not all results were positive. A third of patients who received a dexamethasone implant developed high pressure in the eye – a recognized side effect of steroid injections. Although not painful, it requires treatment with pressure-lowering drops and close follow-up, to prevent glaucoma.

Second, steroid injections accelerate the formation of cataracts (a clouding of the lens of the eye). This requires access to cataract surgery, which is not always easy to arrange in remote locations. Based on these caveats, we developed guidelines for the judicious use of dexamethasone implant in Aboriginal patients, published in March.



Read more: A new way to keep First Nations people living with dementia connected to country, community, family and culture


Reducing the Burden, Bridging the Vision Gap

Although dexamethasone implants are not perfect, we believe the OASIS study offers hope of reducing vision loss and the “burden of treatment” for Indigenous Australians with diabetes.

The ability to perform culturally safe clinical trials means that new treatments could be evaluated in the same way in the future, taking into account patient input through community-controlled research.



Read more: Racism is a public health crisis — but the black death toll isn’t the answer



Source link

]]>